Bluebird's next gene therapy gets backing from European regulator
Dive Brief: A committee that advises Europe's drug regulator is recommending that a gene therapy developed by Bluebird bio for a rare, often deadly disease be approved for market. The disease, known as adrenoleukodystrophy or ALD for short, is caused by genetic mutations that lead to a toxic buildup of molecules in the brain and spinal cord. In clinical testing, Bluebird's therapy, now called Skysona, has shown positive effects on cerebral ALD — the most common and severe form of the disease — with the vast majority of treated patients staying alive and free of major functional disabil...